MMR vaccination and disease elimination: the Finnish experience
- PMID: 20822347
- DOI: 10.1586/erv.10.99
MMR vaccination and disease elimination: the Finnish experience
Abstract
Measles, mumps and rubella (MMR) vaccinations have been included in Finland's national vaccination program as a two-dose schedule since 1982. Owing to the high (>95%) coverage of vaccinations, indigenous MMR diseases were eliminated from Finland by the mid-1990s. In 1982, the incidence of measles, mumps and rubella was 105, 43 and 64 per 100,000 population, respectively, but declined to 0.1 per 100,000 population for all MMR diseases in 1995. Since then, the few cases of measles, mumps and rubella imported annually have not caused any outbreaks. Several research projects that started along with the vaccination campaign have provided important support throughout the program. The vaccine was proven to be safe, immunogenic and effective. Antibody follow-up has revealed that MMR vaccine-induced antibodies wane over time, and concerns have arisen about the continuation of this good situation. High vaccination coverage, enhanced surveillance and preparedness to administer additional doses when needed are key factors for future success. Here we present an overview of MMR vaccinations and the Finnish experience of the MMR disease elimination process, and we describe surveillance activities in the era following elimination in Finland.
Similar articles
-
The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.N Engl J Med. 1994 Nov 24;331(21):1397-402. doi: 10.1056/NEJM199411243312101. N Engl J Med. 1994. PMID: 7969278
-
An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.J Infect Dis. 2004 May 1;189 Suppl 1:S131-45. doi: 10.1086/378987. J Infect Dis. 2004. PMID: 15106102
-
Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.J Infect Dis. 2008 Apr 1;197(7):950-6. doi: 10.1086/528993. J Infect Dis. 2008. PMID: 18419470
-
Measles, mumps, rubella prevention: how can we do better?Expert Rev Vaccines. 2021 Jul;20(7):811-826. doi: 10.1080/14760584.2021.1927722. Epub 2021 Jun 7. Expert Rev Vaccines. 2021. PMID: 34096442 Review.
-
The virtual elimination of rubella and mumps from the United States and the use of combined measles, mumps and rubella vaccines (MMR) to eliminate measles.Dev Biol Stand. 1986;65:45-52. Dev Biol Stand. 1986. PMID: 3104117 Review.
Cited by
-
Susceptibility to measles, mumps, and rubella in 5-year-old children in Flanders, Belgium.Eur J Pediatr. 2015 Jul;174(7):925-32. doi: 10.1007/s00431-014-2481-5. Epub 2015 Jan 13. Eur J Pediatr. 2015. PMID: 25579232
-
Synthesis of Evidence to Characterize National Measles and Rubella Exposure and Immunization Histories.Risk Anal. 2016 Jul;36(7):1427-58. doi: 10.1111/risa.12454. Epub 2015 Aug 6. Risk Anal. 2016. PMID: 26249328 Free PMC article.
-
Outbreak-related mumps vaccine effectiveness among a cohort of children and of young adults in Germany 2011.Hum Vaccin Immunother. 2014;10(1):140-5. doi: 10.4161/hv.26642. Epub 2013 Oct 7. Hum Vaccin Immunother. 2014. PMID: 24091837 Free PMC article.
-
Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.BMJ Open. 2015 Sep 11;5(9):e007202. doi: 10.1136/bmjopen-2014-007202. BMJ Open. 2015. PMID: 26362659 Free PMC article. Clinical Trial.
-
Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage.J Infect Dis. 2013 Jul;208(1):10-6. doi: 10.1093/infdis/jit143. Epub 2013 May 8. J Infect Dis. 2013. PMID: 23661802 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
